ATE418542T1 - Als ccr5-antagonisten verwendbare aryloxim- piperazine - Google Patents

Als ccr5-antagonisten verwendbare aryloxim- piperazine

Info

Publication number
ATE418542T1
ATE418542T1 AT02731174T AT02731174T ATE418542T1 AT E418542 T1 ATE418542 T1 AT E418542T1 AT 02731174 T AT02731174 T AT 02731174T AT 02731174 T AT02731174 T AT 02731174T AT E418542 T1 ATE418542 T1 AT E418542T1
Authority
AT
Austria
Prior art keywords
aryloxim
piperazine
usable
ccr5 antagonists
ccr5
Prior art date
Application number
AT02731174T
Other languages
English (en)
Inventor
John Clader
Sue-Ing Lin
Stuart Mccombie
Pradeep Pushpavanam
Susan Vice
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE418542T1 publication Critical patent/ATE418542T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02731174T 2001-03-29 2002-03-27 Als ccr5-antagonisten verwendbare aryloxim- piperazine ATE418542T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27995001P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
ATE418542T1 true ATE418542T1 (de) 2009-01-15

Family

ID=23071025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731174T ATE418542T1 (de) 2001-03-29 2002-03-27 Als ccr5-antagonisten verwendbare aryloxim- piperazine

Country Status (18)

Country Link
US (1) US6689783B2 (de)
EP (1) EP1373206B1 (de)
JP (1) JP4303969B2 (de)
KR (1) KR20030083015A (de)
CN (1) CN1253435C (de)
AR (1) AR033622A1 (de)
AT (1) ATE418542T1 (de)
AU (1) AU2002303168B2 (de)
CA (1) CA2442210C (de)
DE (1) DE60230491D1 (de)
ES (1) ES2318009T3 (de)
HU (1) HUP0400389A3 (de)
IL (1) IL157713A0 (de)
MX (1) MXPA03008801A (de)
MY (1) MY134019A (de)
NZ (1) NZ528011A (de)
WO (1) WO2002079157A1 (de)
ZA (1) ZA200307171B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
DE602005013931D1 (de) * 2004-02-05 2009-05-28 Schering Corp
WO2005101838A2 (en) 2004-04-13 2005-10-27 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US20070215685A1 (en) * 2005-02-03 2007-09-20 Yottamark, Inc. System and Method of Product Identification Using a URL
AU2006216731A1 (en) * 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
KR100830003B1 (ko) * 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법
US20080173808A1 (en) * 2007-01-18 2008-07-24 Schering Corporation Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms)
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2021165960A1 (en) 2020-02-19 2021-08-26 Ichilov Tech Ltd. Improved antidepressant therapy
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
NZ230045A (en) 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CA2212370A1 (en) 1995-02-16 1996-08-22 Moses Judah Folkman Inhibition of angiogenesis using interleukin-12
TR200103214T2 (tr) 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.

Also Published As

Publication number Publication date
HUP0400389A2 (hu) 2004-08-30
HUP0400389A3 (en) 2008-03-28
CN1500078A (zh) 2004-05-26
JP4303969B2 (ja) 2009-07-29
US6689783B2 (en) 2004-02-10
EP1373206B1 (de) 2008-12-24
DE60230491D1 (de) 2009-02-05
JP2004524360A (ja) 2004-08-12
AR033622A1 (es) 2003-12-26
EP1373206A1 (de) 2004-01-02
CA2442210C (en) 2009-09-08
US20030087912A1 (en) 2003-05-08
IL157713A0 (en) 2004-03-28
ES2318009T3 (es) 2009-05-01
CN1253435C (zh) 2006-04-26
CA2442210A1 (en) 2002-10-10
ZA200307171B (en) 2004-12-13
HK1057211A1 (en) 2004-03-19
KR20030083015A (ko) 2003-10-23
MY134019A (en) 2007-11-30
NZ528011A (en) 2004-08-27
AU2002303168B2 (en) 2005-10-06
MXPA03008801A (es) 2004-02-18
WO2002079157A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE525378T1 (de) Himbacinanaloga als thrombinrezeptorantagonisten
DE60308850D1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
NO20050429D0 (no) Substituert kinolin-CCR5-reseptorantagonister
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
NO20052739D0 (no) CCR5-antagonister som medikamenter
DE60134094D1 (de) C7-taxanester als antitumormittel
DE60110844D1 (de) Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
NO20023424L (no) Kortikotropin-frigjörende faktorantagonister
DE60305903D1 (de) Tropanderivative als ccr5-modulatoren
ATE299868T1 (de) Dihydro-benzo (b) (1,4) diazepin-2-on-derivate als mglur2 antagonisten
ATE392897T1 (de) Chinolinderivate als npy antagonisten
PT1421075E (pt) Derivados de piperdina uteis como antagonistas do ccr5
ATE439344T1 (de) Muscarin-antagonisten
DE60202761D1 (de) Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
ATE403651T1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
ATE469875T1 (de) Nk1-antagonisten
SI1425280T1 (sl) Hetero-biciklicni antagonisti crf
DE60222693D1 (de) Nk1-antagonisten
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine
DE60207399D1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
DE60226419D1 (de) Somatostatin-antagonisten
DE50206910D1 (de) Substituierte y-lactonverbindungen als nmda-antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties